Mudit is a Founding General Partner of Treo Ventures, and the CEO and co-founder of NuXcel, a bioelectronics focused medical device accelerator. Mudit also co-founded and serves as Chairman of the Board at ShiraTronics, Inc., Avivomed, Inc. and iVEAcare, Inc.
Mudit brings over two decades of medical device industry experience across company formation, R&D, business development, and venture capital, with a global perspective on healthcare based on his experiences in USA, Ireland, and India. Mudit has served on the boards of several medical device companies, from early concept to commercial growth stage, resulting in successful IPOs and M&A transactions.
Mudit currently serves on the boards of CVRx, (NSDQ: CVRX), Avivomed, Inc., InterVene, Inc., iVEAcare, Inc., Neuspera Medical, Inc., ShiraTronics, Inc., NeoChord, Inc., SecondWave Systems, Inc., and NuXcel. Some of his prior investments/board responsibilities include Inspire Medical Systems (NYSE: INSP), iRhythm Technologies (NSDQ: IRTC), Aptus Endosystems (Acqd. by Medtronic), CardioMEMS (Acqd. by St. Jude Medical), and Impres Medical (Acqd. by J&J).
Mudit also serves on the External Advisory Board for Cleveland Clinic Innovations, Board of Visitors of the Graduate School at Duke University, External Advisory Board of John Hopkins University Center for Bioengineering Innovation and Design, and on the Board of One Heart Health, a healthcare focused non-profit focused on providing access to pediatric populations in underprivileged geographies.
Most recently, as a General Partner with Synergy Life Science Partners, Mudit delivered top quartile performance. In addition to his private venture capital experiences at Treo and Synergy Life Science Partners, Mudit also brings a strategic investment perspective gained during his tenure at Johnson & Johnson Development Corporation.
Prior to his investing career, Mudit held operational roles in the Cardiac Rhythm Management Division of Guidant Corporation, developing novel device technologies for heart failure, remote monitoring, and cardiac ablation. Mudit also played an important role in product development for start-ups like Epicor, Inc. (acquired: St. Jude Medical), and Cardiac Pathways Corporation (acquired: Boston Scientific). Mudit holds eight issued patents and has authored several peer reviewed publications.
Mudit graduated with a B.E. in Electrical Engineering from VNIT, Nagpur, India, where he was a gold medal recipient for academic achievements. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from The Wharton Business School, University of Pennsylvania.
